Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Modulation of STAT3 Signaling With Siltuximab in Type 1 Diabetes

NCT02641522 is registered in ClinicalTrials.gov with Carla Greenbaum, MD as lead sponsor.

NCT NCT02641522
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02641522 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Modulation of STAT3 Signaling With Siltuximab in Type 1 Diabetes
Lead sponsor
Carla Greenbaum, MD
Phase
Phase 1
Overall status
Completed
Start date
March 8, 2016
Completion date
March 16, 2017
Enrollment
10 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

type 1 diabetes